Results 71 to 80 of about 623,776 (234)
The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle
ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley +1 more source
Selective Phosphodiesterase 4B Inhibitors: A Review
, 2014 Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation.
Mohammed AZAM, Naga TRIPURANENI
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger +15 more
wiley +1 more source
ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors—A STING in the Tale of ENPP1
Molecules, 2019 Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) was identified several decades ago as a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities, critical for purinergic signaling. Recently,
Kenneth I. Onyedibe +2 more
doaj +1 more source
Pulmonary Circulation, 2020 Pulmonary Hypertension due to left heart disease is the most common type of Pulmonary Hypertension. Morbidity and mortality significantly increase once Pulmonary Hypertension is present.
Galo M. Sanchez Palacios +2 more
doaj +1 more source
, 2013 The treatment of pulmonary arterial hypertension (PAH) has undergone significant change in recent years, improving both quality of life and survival for patients.
Wardle, Andrew James, Tulloh, Robert M R
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr +15 more
wiley +1 more source
Phosphodiesterase 4 inhibitors : apremilast and roflumilast
, 2016 Inhibitors of phosphodiesterase 4 (PDE4) are anti-inflammatory drugs that have been evaluated for the treatment of several inflammatory diseases.
Pile, Kevin (R17082) +3 more
core +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
European Journal of Organic Chemistry, EarlyView.A practical strategy for synthesizing β‐ and γ‐carbolinones from indole‐based Ugi 4‐CR adducts through an intramolecular radical cyclization using Fe(III)–H species is presented. This approach enables the efficient synthesis of spiro‐carbolinones under mild reaction conditions and demonstrates the effectiveness of secondary radicals in both cyclization
María F. Olvera‐Granados +1 more
wiley +1 more source